ArticleBMC cancer2026
Clinical characteristics and long-term treatment outcomes in childhood myelodysplastic neoplasm: a nationwide population-based study in Korea.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundChildhood myelodysplastic neoplasm (cMDS) is a rare condition with distinct biological and clinical characteristics. To characterize the epidemiological features of cMDS, including incidence, demographics, and underlying etiologies. We also aimed to identify prognostic factors and assess long-term outcomes associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with cMDS.
methodsThis nationwide Korean study analyzed 484 patients < 19 years of age diagnosed with cMDS between 2003 and 2021, using data from the Korean National Health Insurance Service database.
resultsAnnual incidence ranged from 1.7 to 4.3 per million children, with 7.2% had a prior history of malignancy. A total of 180 patients underwent allo-HSCT for cMDS. The 5-year overall survival (OS) rates were 76.6% in the transplant group and 80.5% in the non-transplant group. Among non-transplanted patients, key prognostic factors included later period of diagnosis (hazard ratio [HR] 0.372, P = 0.012), history of prior malignancy (HR 3.329, P = 0.002), and chemotherapy for cMDS (HR 3.701, P = 0.002). Only CBT was significantly associated with increased mortality in univariate analysis of the transplant group (HR, 3.911; P = 0.008). The 10-year cumulative incidence of leukemia was 20.5%, with a significantly higher rate in the cMDS with increased blasts (cMDS-IB) group (53.3% vs. 19.4%, P = 0.002).
conclusionsWhile many patients achieved stable disease control without allo-HSCT, monitoring remains essential due to the risk of leukemic transformation, particularly in therapy-related and cMDS-IB subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.